ONCO - Onconetix Inc

ONCO - Onconetix Inc

https://www.onconetix.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. ( NASDAQ: ONCO )

Benzinga • 1 month, 4 weeks ago • score: 0.28

NEW YORK, July 17, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Benzinga • 1 month, 4 weeks ago • score: 0.34

CINCINNATI, July 16, 2025 ( GLOBE NEWSWIRE ) -- Onconetix, Inc. ONCO ( "Onconetix" or the "Company" ) and Ocuvex Therapeutics, Inc. ( "Ocuvex" ) , a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that ...

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

GlobeNewswire • 1 month, 4 weeks ago • score: 0.35

CINCINNATI, July 16, 2025 ( GLOBE NEWSWIRE ) -- Onconetix, Inc. ( Nasdaq: ONCO ) ( "Onconetix" or the "Company" ) and Ocuvex Therapeutics, Inc. ( "Ocuvex" ) , a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today ...

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

GlobeNewswire • 2 months, 4 weeks ago • score: 0.15

CINCINNATI, Ohio, June 16, 2025 ( GLOBE NEWSWIRE ) -- Onconetix, Inc. ( Nasdaq: ONCO ) ( "Onconetix" or the "Company" ) , a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today reported ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$552.50

52W Low

$2.61

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.36

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

0.00

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.47

EV/Revenue (<3 favorable)

9.62

P/S (TTM) (<3 favorable)

3.24

P/B (<3 favorable)

0.73

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

19.74%

Institutions (25–75% balanced)

0.60%

Shares Outstanding

1,545,700

Float

1,240,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,327,000

Gross Profit (TTM)

881,720

EPS (TTM)

2044.06

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-12.60%

ROE (TTM) (>15% strong)

-11.80%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.85

Momentum

Bearish momentum

Value

-0.1223

Previous

-0.1510

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025